Vator Securities acted as Sole Bookrunner and Advisor in connection with Ascelia Pharmas Pre-IPO share issue
Vator Securities acted as Sole Bookrunner and Advisor in connection with the transaction raising SEK 60 million.Ascelia Pharma is a Swedish-based specialty oncology drug development company with a late stage pipeline of products with potential to significantly improve survival in cancer patients. The lead asset Mangoral® is a novel MR imaging (MRI) drug, which is being developed for detection of liver metastases in patients with severely impaired kidney function who are at risk of serious side effects if given any of the current imaging drugs on the market. Today, these patients have no